[1]
Roussel, E. et al. 2020. Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma. Scandinavian Journal of Urology. 54, 6 (Nov. 2020), 493–499. DOI:https://doi.org/10.1080/21681805.2020.1814858.